Indian Pharmaceutical Alliance drops opposition to Gilead's Sovaldi patent

15 September 2015

The Indian Pharmaceutical Alliance (IPA) has dropped its opposition to Gilead Sciences’ (Nasdaq: GILD) patent application for Sovaldi (sofosbuvir), as the company has voluntarily made a licensing agreement with 11 companies to sell a lower-cost generic, according to local media reports.

The hepatitis C treatment is sold by Gilead for $1,000 per pill in the USA.

Natco Pharma, based in Hyderabad, India, filed a pre-grant opposition with the Indian Patent Office, and also pulled out from litigation as it became one of the companies with which Gilead entered into a licensing agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK